Xilio Therapeutics Analyst Ratings
Xilio Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/21/2022 | 255.33% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 11/10/2022 | 559.9% | Raymond James | $31 → $13 | Maintains | Outperform |
| 08/10/2022 | 915.23% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
| 01/10/2022 | 1727.41% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
| 11/16/2021 | 1473.6% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
| 11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/16/2021 | 1524.37% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 12/21/2022 | 255.33% | 查尔丹资本 | → $7 | 开始承保 | →购买 |
| 11/10/2022 | 559.9% | 雷蒙德·詹姆斯 | $31 → $13 | 维护 | 跑赢大盘 |
| 08/10/2022 | 915.23% | 摩根士丹利 | $32 → $20 | 维护 | 超重 |
| 01/10/2022 | 1727.41% | HC Wainwright公司 | → $36 | 开始承保 | →购买 |
| 11/16/2021 | 1473.6% | 雷蒙德·詹姆斯 | → $31 | 开始承保 | →跑赢大盘 |
| 11/16/2021 | — | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 11/16/2021 | 1524.37% | 摩根士丹利 | → $32 | 开始承保 | →超重 |
What is the target price for Xilio Therapeutics (XLO)?
希利奥治疗公司(XLO)的目标价格是多少？
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Chardan Capital on December 21, 2022. The analyst firm set a price target for $7.00 expecting XLO to rise to within 12 months (a possible 255.33% upside). 4 analyst firms have reported ratings in the last year.
查尔丹资本于2022年12月21日报道了西里奥治疗公司(纳斯达克：XLO)的最新目标价。这家分析公司将目标价定为7美元，预计XLO将在12个月内升至(可能上涨255.33%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Xilio Therapeutics (XLO)?
希利奥治疗公司(XLO)的最新分析师评级是多少？
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Chardan Capital, and Xilio Therapeutics initiated their buy rating.
纳斯达克(Sequoia Capital：XLO)的最新分析师评级是由查尔丹资本提供的，希利奥治疗公司启动了买入评级。
When is the next analyst rating going to be posted or updated for Xilio Therapeutics (XLO)?
Xilio治疗公司(XLO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on December 21, 2022 so you should expect the next rating to be made available sometime around December 21, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与希利奥治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Xilio治疗公司的上一次评级是在2022年12月21日提交的，所以你应该预计下一次评级将在2023年12月21日左右提供。
Is the Analyst Rating Xilio Therapeutics (XLO) correct?
分析师对Xilio Treeutics(XLO)的评级正确吗？
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a initiated with a price target of $0.00 to $7.00. The current price Xilio Therapeutics (XLO) is trading at is $1.97, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Xilio治疗公司(XLO)评级是以0.00美元至7.00美元的目标价启动的。希利奥治疗公司(XLO)目前的交易价格为1.97美元，在分析师的预测范围内。